Add-on pralidoxime therapy did not offer any appreciable benefit over atropine alone in terms of reducing mortality ( 18.33 % ( 11/60 ) versus 13.33 % ( 8/60 ) ) and ventilator requirement ( 5 % ( 3/60 ) versus 8.33 % ( 5/60 ) ) .